BioConsult4.0
"Embracing the Future"
Introducing Industry 4.0.
January 20, 2021
With increasing R&D costs and clinical trial's failures, the biopharmaceutical industry is facing numerous challenges.
Moreover, the production of personal medicines such as Cell & Gene therapy products poses new challenges such as small production scale, batch quality variability and high production cost. The adoption of Industry 4.0 technologies by biopharmaceutical companies can help overcome those challenges. In this short article, I attempted to put Industry 4.0 into perspective, define it, and present its principles and some of its most prominent technologies and concepts.
Too little, too late: a critical reflection on senolytic drugs usage in Idiopathic Pulmonary Fibrosis (IPF) treatment.
July 09, 2020
Here is a short article in which I share my thoughts on Senolytic drugs potential in the treatment of Idiopathic Pulmonary Fibrosis.
In the article, I elaborated on four critical aspects.
1) Clinical Trial design.
2) Unanswered question regarding the Bystander effect.
3) The limitation of senolytic drugs usage.
Preclinical success, clinical failure: How to close the gap in Idiopathic Pulmonary Fibrosis drug development?
March 27, 2020
Here is a short article in which I share my thoughts on preclinical research and clinical trials for Idiopathic Pulmonary Fibrosis.
In the article, I elaborated on four critical aspects.
1) The selection of in vivo models
2) The timing of therapeutic intervention
3) The importance of human tissues
4) And experimental design to strengthen results.